<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02954341</url>
  </required_header>
  <id_info>
    <org_study_id>SJM-CIP-10147</org_study_id>
    <nct_id>NCT02954341</nct_id>
  </id_info>
  <brief_title>CardioMEMS HF System OUS Post Market Study</brief_title>
  <official_title>CardioMEMS HF System OUS Post Market Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Post Market Study (PMS) is to evaluate the use of the CardioMEMS HF&#xD;
      System in patients with Class III Heart Failure in a commercial setting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from device/system related complications</measure>
    <time_frame>Two year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from pressure sensor failure.</measure>
    <time_frame>Two year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Annualized HF hospitalization rate at 1 year compared to the HF hospitalization rate in the year prior to enrollment.</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Heart Failure</condition>
  <condition>Left-Sided Heart Failure</condition>
  <condition>Congestive Heart Failure</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CardioMEMS HF System</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with New York Heart Association (NYHA) Class III Heart Failure (HF) who have&#xD;
        experienced a heart failure hospitalization within the past 12 months.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent obtained from subject&#xD;
&#xD;
          2. ≥ 18 years of age&#xD;
&#xD;
          3. Diagnosis of NYHA Class III Heart Failure&#xD;
&#xD;
          4. At least 1 HF hospitalization within 12 months of Baseline visit&#xD;
&#xD;
          5. Subjects with reduced LVEF heart failure should be receiving a beta blocker for 3&#xD;
             months and an ACE-I or ARB for one month unless in the investigator's opinion, the&#xD;
             subject is intolerant to beta blockers, ACE-I or ARB.&#xD;
&#xD;
          6. Subjects with a BMI ≤ 35. Subjects with BMI &gt;35 will require their chest circumference&#xD;
             to be measured at the axillary level, if &gt; 65 inches the patient will not be eligible&#xD;
             for the study.&#xD;
&#xD;
          7. Subjects with pulmonary artery branch diameter ≥ 7mm - (implant target artery -&#xD;
             assessed during the RHC)&#xD;
&#xD;
          8. Subjects willing and able to comply with the follow-up requirements of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with an active infection&#xD;
&#xD;
          2. Subjects with history of recurrent (&gt; 1) pulmonary embolism or deep vein thrombosis&#xD;
&#xD;
          3. Subjects who, in the Investigator's opinion, are unable to tolerate a right heart&#xD;
             catheterization&#xD;
&#xD;
          4. Subjects who have had a major cardiovascular event (e.g., myocardial infarction, open&#xD;
             heart surgery, stroke, etc.) within 2 months of Baseline Visit&#xD;
&#xD;
          5. Subjects with Cardiac Resynchronization Device (CRT) implanted &lt; 3 months prior to&#xD;
             enrollment&#xD;
&#xD;
          6. Subjects with a Glomerular Filtration Rate (GFR) &lt; 25 ml/min (obtained within 2 weeks&#xD;
             of the baseline visit) who are non-responsive to diuretic therapy or who are on&#xD;
             chronic renal dialysis&#xD;
&#xD;
          7. Subjects with congenital heart disease or mechanical right heart valve(s)&#xD;
&#xD;
          8. Subjects likely to undergo heart transplantation or VAD within 6 months of baseline&#xD;
             visit&#xD;
&#xD;
          9. Subjects with known coagulation disorders&#xD;
&#xD;
         10. Subjects with a hypersensitivity or allergy to aspirin, and/or clopidogrel (not&#xD;
             applicable for subjects taking anti-coagulation therapy or other approved&#xD;
             anti-platelets therapy).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin R Cowie, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Brompton &amp; Harefield NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maxime De Groof</last_name>
    <email>maxime.degroof@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Poornima Sood</last_name>
    <email>Poornima.sood@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHR Citadelle</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Troisfontaines, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kasper Rossing, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Bromptom Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 21, 2016</study_first_submitted>
  <study_first_submitted_qc>November 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2016</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

